Cleocin phosphate injection for serious bacterial infections

Cleocin phosphate is an injectable antibiotic used to treat serious infections caused by susceptible bacteria, including anaerobic infections and infections with certain streptococci, pneumococci, and staphylococci. It is reserved for patients allergic to penicillin or when penicillin is inappropriate, and it is administered via intramuscular or intravenous routes.

Cleocin phosphate injection is approved for the treatment of serious infections caused by susceptible anaerobic bacteria and certain gram-positive bacteria. Specific indications include:

• Lower respiratory tract infections such as pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae (penicillin-susceptible strains), other streptococci (except Enterococcus faecalis), and Staphylococcus aureus.
• Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes.
• Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes.
• Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic bacteria.
• Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes.
• Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in chronic bone and joint infections.

Use should be based on bacteriologic studies when possible and reserved for proven or strongly suspected bacterial infections.

Clindamycin phosphate

Cleocin phosphate is converted in the body to active clindamycin, which works by binding to the 23S ribosomal RNA of the 50S bacterial ribosomal subunit. This binding inhibits bacterial protein synthesis, leading to a bacteriostatic effect against susceptible bacteria, including anaerobes and certain gram-positive organisms.

Adults: For serious infections caused by aerobic gram-positive cocci and susceptible anaerobes (excluding some species like Bacteroides fragilis): 600 to 1,200 mg per day divided into 2 to 4 doses.
For more severe infections, especially involving Bacteroides fragilis, Peptococcus species, or non-perfringens Clostridium species: 1,200 to 2,700 mg per day divided into 2 to 4 doses. In life-threatening infections, doses may be increased up to 4,800 mg daily intravenously.
Single intramuscular injections over 600 mg are not recommended.

Route and administration: Intramuscular injections should be given undiluted.
Intravenous administration requires dilution and infusion diluted over 10 to 60 minutes, not as an undiluted bolus.

Pediatric patients (1 month to 16 years): Recommended dosing is 20 to 40 mg/kg/day divided every 6 to 8 hours.

Adjustments: No dosage modification necessary for patients with renal or hepatic impairment; monitor patients with severe liver disease. Avoid use in meningitis due to poor cerebrospinal fluid penetration.

History of hypersensitivity to clindamycin or lincomycin preparations.

Clostridioides difficile-associated diarrhea (CDAD): Cleocin phosphate has been associated with CDAD, which can range from mild diarrhea to fatal colitis. CDAD may occur during or up to two months after antibiotic use. If suspected or confirmed, discontinue non-CDAD antibiotics and manage fluid, electrolyte balance, and provide specific therapy against C. difficile.

Hypersensitivity reactions: Anaphylaxis, severe skin reactions including toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. Discontinue immediately if severe reactions develop.

Benzyl alcohol toxicity: Contains benzyl alcohol preservative, which can cause "gasping syndrome" and death in neonates, especially premature or low birth weight infants.

Nephrotoxicity: Potential for acute kidney injury; monitor renal function in at-risk patients; discontinue if injury occurs without other cause.

Meningitis: Not effective due to poor cerebrospinal fluid penetration and should not be used.

Common: Diarrhea, nausea, vomiting, abdominal pain, skin rash (maculopapular, morbilliform-like), injection site irritation or pain, metallic taste after high IV doses.

Serious: Clostridioides difficile colitis, pseudomembranous colitis, anaphylaxis, severe skin reactions (TEN, SJS, DRESS), acute kidney injury, eosinophilia, neutropenia, thrombocytopenia, injection site sterile abscess, thrombophlebitis, polyarthritis, cardiopulmonary arrest and hypotension with rapid IV administration.

Cleocin is metabolized primarily by CYP3A4 and to a lesser extent CYP3A5. Strong CYP3A4 inhibitors may increase clindamycin levels, requiring close monitoring for toxicity. Strong CYP3A4 inducers like rifampicin may reduce its effectiveness. Use caution with other neuromuscular blocking agents as clindamycin may enhance their effects.

Pregnancy: Clindamycin has not shown teratogenic effects in animal studies or in second and third trimester human use. Use during the first trimester only if clearly needed. Contains benzyl alcohol which crosses the placenta.

Lactation: Clindamycin is present in breast milk in low concentrations and can affect infant gut flora, possibly causing diarrhea or candidiasis. Breastfeeding need not be discontinued but monitor the infant for adverse effects.

Signs observed in animal studies include convulsions and depression. Hemodialysis and peritoneal dialysis do not effectively remove clindamycin. Supportive care is indicated in overdose.